



www.motilaloswal.com





LargeCap	Mid cap
Bharti Airtel	Max Healthcare
ICICI Bank	Marico
Mahindra & Mahindra	SRF
Hindustan Aeronautics	Hindustan Petroleum
Varun Beverages	Niva Bupa





# Valuation snapshot

Preferred Large/Mid Cap Stocks	M. Cap	(₹)	Target (₹)	Upside (%)	EPS CAGR FY25- FY27E (%)	PE (x) FY25E FY27E		PB (x) FY25E FY27E		RoE (%) FY25E FY27E	
Large Cap											
Bharti Airtel	10,812	1,883	1,990	6%	30%	50.8	29.8	10.1	6.6	22.8	25.6
ICICI Bank	10,208	1,435	1,650	15%	13%	21.4	16.7	3.5	2.7	18.0	17.5
M&M	3,746	3,119	3,482	12%	15%	29.8	22.5	5.7	4.2	20.8	20.0
HAL	3,071	4,470	5,100	14%	29%	48.1	28.9	9.1	6.5	18.9	22.5
VBL	1,815	512	665	30%	26%	68.3	43.1	10.7	7.9	22.0	19.7
Mid/Small Cap											
Max Healthcare	1,104	1,152	1301	13%	30%	71.0	41.8	9.9	6.9	14.9	17.9
Marico	942	736	800	9%	10%	55.4	45.4	22.7	20.5	41.8	46.3
SRF	888	3056	3,520	15%	53%	69.6	29.7	7.2	5.4	10.7	19.7
HPCL	873	397	455	15%	22%	12.1	8.2	1.6	1.2	13.7	15.8
Niva Bupa	162	81	100	23%	38%	98.8	52.0	5.0	4.4	6.0	8.9

Price as on 7th May 2025







## Markets Rally in April on Easing Tariff Tensions, Strong Flows, and In-line Earnings

- Equity markets continued to show strength in April, on the back of easing global tariff tensions, in-line Q4 results so far, positive inflows from both FIIs & DIIs and healthy domestic macros. Nifty gained for the second successive month in Apr'25 (+3.5% MoM) and recorded its second-best monthly returns in the last nine months. Nifty Midcap 100 rose by +4.8% and Smallcap 100 was up 2.2%.
- On the global front, the US President announced a 90-day pause on 'reciprocal tariffs' for most countries, effective April 9, 2025 in an effort to provide time for trade negotiations. This move helped ease market concerns and alleviated fears of a potential global economic slowdown.
- Fils remained net buyers for 2nd month in a row with inflows of ₹ 2,735 crore in Apr'25, while DII inflows remained remain robust at ₹ 28,228 crore.

- Earnings of the 27 Nifty companies that have declared results as of 5th May'25 have grown 4% YoY, outperforming our estimate of +2% YoY. Earnings of 109 MOFSL coverage companies grew 6% compared to estimate of -2% YoY decline in 4QFY25.
- The earnings growth was fuelled by Metals (profit surged 67% YoY on a low base), Technology (7% YoY), BFSI (2% YoY), and Oil & Gas (OMC's profit grew 14% vs. our est. of a 63% decline). In contrast, earnings growth was hit by Real Estate (-10%), PSU Banks (-6%), and NBFC Non-Lending (-7%).
- The market has rebounded smartly over the last two months, entirely erasing its YTD decline. The Nifty is currently trading 2.9% higher in CY25YTD. With the current rally, Nifty trades at 21x FY26 PE, near its longterm average of 20.6x. Near-term challenges such as global macros, developments on the US negotiations, geo-political and tensions between India and Pakistan, may keep the market volatile and jittery. However, we believe that the medium to long-term narrative for India remains positive.







Focus likely to intensify on capital allocation plans

#### **Key Rationales**

- Bharti Airtel's FCF generation has improved significantly over the past few years (9MFY25: INR292b), driven by tariff repair in the India wireless segment. Main priority for cash deployment so far has been prepaying high-cost debt.
- With a complete flow-through of tariff hikes and a moderation in capex intensity, Bharti is likely to generate significant FCF (~INR1.3t over FY25-27E).
- With high-cost debt largely repaid and leverage under control, we believe capital allocation remains the key monitorable.
- Dividend pay-out may increase to INR 14 per share in FY25, helping promoter entity service its debt.
- We expect ~15%/19% in consol. revenue/EBITDA CAGR over FY24-27, led by India wireless ARPU growth of 12.5% and strong performance in Africa.

- ICICI Bank reported a healthy Q4 performance with PAT ₹126b (5% beat, 18% YoY growth), driven by robust NIM expansion, healthy other income, controlled provisions and contained operating expenses.
- ICICI Bank posted 11% YoY NII growth with NIM rising by 16bp QoQ to 4.41%. Net advances grew 13% YoY, while deposits rose 14% YoY.
- Secured asset quality remained stable (excl. agri) with no signs of stress, leading to an improvement in the GNPA ratio.
- We upgrade our earnings estimates by 2.5%/4.2% for FY26/FY27 on the back of positive NIM surprise and controlled credit cost. We thus estimate RoA/RoE of 2.3%/17.5% in FY27. ICICI remains our top preference in the sector



Set for top performance with robust loan growth







FES performance impresses; drives margin beat

#### **Key Rationales**

- Mahindra & Mahindra delivered a strong 4QFY25 performance, revenue grew 24.5% YoY, and EBITDA margin expanded 180bp YoY to 14.9%, driven by improved ASPs across both the Auto and FES segments.
- Management remains confident of outperforming the tractor industry in FY26, supported by a favorable market mix & high single-digit industry growth expectations. UV outperformance is expected to sustain in FY26 driven by strong rural recovery and full-year benefit of new launches.
- MM surpassed its FY24–25 EPS and RoE targets of 18%, and has reiterated its long-term guidance of 15–20% EPS growth and 18% RoE.
- We estimate MM to post a CAGR of ~13%/13%/18% in revenue/EBITDA/PAT over FY25-27E



Well positioned!

- Hindustan Aeronautics (HAL) is a market leader in aerospace defense. It boasts a strong order book of ₹1.8t as of Mar'25.
- With a medium-term pipeline of ₹2.4t & long-term market potential of ₹6t, it is set to benefit from projects like Tejas Mk1A, Su-30 Mk1, & Tejas Mk2.
- HAL is well-positioned for growth due to the strong support from the Indian government's growing defense budget, which is set to rise by 13% YoY in FY26 to INR 1.8 trillion.
- We expect the company's overall revenue to record a CAGR of 29% over FY25-27, driven by a significant ramp-up in manufacturing and stable revenue from repairs and spares.
- HAL has successfully overcome supply chain challenges, putting it in a strong position to execute and capture the expanding opportunities in India's defence sector.







Double-digit volume growth in domestic market despite intensifying competition

#### **Key Rationales**

- Varun Beverages delivered strong 1QCY24 performance with 29% YoY revenue growth, driven by robust 30% volume growth (15.5% organic).
- While margins remained flat YoY at 22.7% due to lower-margin South Africa consolidation, domestic demand stayed healthy with double-digit growth.
- VBL maintained its volume growth trajectory in the domestic market & its expansion in international markets. Management is confident about its double-digit growth guidance on the back of industry tailwinds and expansion into new markets.
- We project 18%/16%/26% revenue/EBITDA/PAT CAGRS over CY25-26. As PepsiCo's key franchisee, VBL is well-placed to capitalize on India's underpenetrated beverage market and rural refrigeration growth.



Volume and realization drive earnings

- Max Healthcare is well-positioned as a leading multi-specialty hospital chain, to expand its bed capacity by at least 30% in FY26, reaching approximately 6,500 beds.
- This includes the addition of over 1,300 beds across facilities like Nanavati-Mumbai, Mohali, Delhi, & Gurugram.
- Max will invest Rs 6,000 crore by 2028 to add 3,700 beds across India, increasing its facilities to around 30 hospitals.
- The expansion, funded internally, includes the recent inauguration of a 300-bed hospital in Dwarka, Delhi one of four hospitals due to open this year
- We remain positive on MAXH on the back of: 1) superior execution of its operational centers and b) a robust plan to sustain growth momentum
- We expect a 17% revenue CAGR over FY25-27.








Robust toplines growth; near-term margin pressure persists

#### **Key Rationales**

- Marico reported 20% YoY growth in consol. revenue for 4Q, with domestic revenue rising 23% & volume growth at 7%. International revenue increased by 11% YoY (16% CC growth).
- Domestic revenue growth was driven by strong core category performance & success in Foods & Premium Personal Care.
- International business saw healthy growth, with a significant increase in share of the premium portfolio (20% in FY21 to 29% in FY25).
- Marico launched Project SETU to enhance direct reach & drive growth in general trade channel.
- Marico expects double-digit revenue growth in FY26, supported by pricing, expanded distribution, & strong growth in premium categories. We model 11%/13% revenue EBITDA CAGR during FY25-27E.



- Annual capex of ₹15–20B, along with improved pricing power and product mix, supports long-term profitability.
- Reduction in customs duties on key inputs and government support for EV battery manufacturing will boost demand and margins in both fluorochemicals and specialty chemicals.
- We expect 20%/36%/53% CAGR in revenue/EBITDA/PAT over FY25-27E, with stronger QoQ growth in Chemicals in 4QFY25.



Outlook improves for the Chemicals business







Start-up of multiple projects set to boost earnings

#### **Key Rationales**

- Hindustan Petroleum reported EBITDA 61% above estimates, driven by stronger-than-expected GRM of USD8.5/bbl. & marketing margin of INR4.5/lit, leading to PAT of INR33.5b, (+114% beat).
- HPCL's gas sales volume stood at 1mmt+ (+40% YoY).
   It expects 25-30% YoY growth in volumes.
- The OMC rally may be nearing its end, but nearterm drivers persist: LPG price hike, rising Russian crude intake, & steady marketing margins.
- We favour HPCL for its marketing leverage, dividend appeal, & upcoming project ramp-ups.
- We estimate FY26E RoE of 17.3%, seeing the following catalysts: de-merger & potential listing of the lubricant business, commissioning of the bottom upgrade unit in 2QCY26, start up of Rajasthan refinery in FY26, & improving LPG under-recovery dynamics.

- Niva Bupa reported 18%/25% YoY growth in Gross Written Premium/Net Earned Premium in Q4, driven by 3%/59%/18% growth in retail health/group health/PA businesses.
- It secured business from 2 large corp. accounts, significantly contributing to strong growth in group health.
- With a YoY expansion of 50bp/190bp in commission/expense ratios, the combined ratio improved to better-than-expected 92.8%, up 340bp YoY. Measures taken to mitigate claim inflation will continue to aid loss ratios, while op. efficiency will lead to improved expense ratio going forward.
- Niva is well-positioned to harness growth opportunities with a strategic global partner, a growing customer base, & innovative product offerings. The diversified channel mix will ensure improved scalability as the company moves toward geographic expansion.



Strong underwriting performance boosts PAT





#### Sneha Poddar VP - Retail Research

#### Devanshi Sharma Research Analyst

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on <a href="https://www.motilaloswal.com">www.motilaloswal.com</a>. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities

Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.motilaloswal.com/Dormant/documents/A

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or

more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- $\mbox{\scriptsize a})$  received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- a) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.

  MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.

  MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have

a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened for proprietary investments only.

name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification
The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. Disclosure of interest Statement

Analyst ownership of the stock No

A graph of daily closing prices of securities is available at <a href="www.nseindia.com">www.nseindia.com</a>, Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL& its group companies to registration or licensing requirements within such jurisdictions.

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motifal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motifal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the

United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for

U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S. MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. (\*MOSIPL\*). Any business interaction pursuant to this report will have to be executed within the

provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 27II and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 2011294012) which is a holder of a capital markets services license and an exempt financial adviser in Singapore, as per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "institutional investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL Disclaimer.

This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities- involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may of the infe essing this info n The exempt MOF any of its affiliates responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and

 $harmless from \ all \ losses, costs, damages, expenses that \ may \ be`suffered \ by \ the \ person \ accessing \ this \ information \ due \ to \ any \ errors \ and \ delays.$ This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; <a href="https://www.motilaloswal.com">www.motilaloswal.com</a>. Correspondence Address: Palm Spring

Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@matilaloswal.com, Contact

No.:022:140548085. Qrievence Reducesal Cell: 022 40548000 / 022 67490600

query@motilaloswal.com Ms. Kumud Upadhyay 022 40548082 servicehead@motilaloswal.com Mr. Ajay Menon 022 40548083 am@motilaloswal.com

Registration details of group entities: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN .: 146822. IRDA Corporate Agent -CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to al.com, for DP to <a href="mailto:dpgrievances@motilaloswal.com">dpgrievances@motilaloswal.com</a>